SEC Form 10-Q Summary
Filing identity: The supplied filing is for Nile Therapeutics, Inc., not Capricor Therapeutics, Inc. It covers the unaudited quarter ended March 31, 2012 and was filed May 15, 2012.
Business Context and Reporting Period
Nile was a development-stage biotechnology company developing cardiovascular therapies, primarily cenderitide for heart failure and CU-NP, a preclinical natriuretic peptide. The company had no product sales and depended on equity, debt, grants, and collaboration funding.
Financial Metrics
| Metric | Q1 2012 | Q1 2011 |
|---|---|---|
| Collaboration income | $195,500 | $0 |
| Total income | $195,500 | $0 |
| Research and development expense | $465,353 | $622,332 |
| General and administrative expense | $500,020 | $575,278 |
| Total operating expenses | $965,373 | $1,197,610 |
| Loss from operations | $(769,873) | $(1,197,610) |
| Net loss | $(771,879) | $(1,195,792) |
| Basic and diluted loss per share | $(0.02) | $(0.03) |
| Cash used in operating activities | $(603,460) | $(1,260,501) |
The reported net loss margin was approximately negative 395% of total income in Q1 2012; comparisons are not meaningful because income consisted of collaboration reimbursement rather than product revenue. Stock-based compensation was $171,815 in the quarter, compared with $267,174 in Q1 2011.
| Balance-sheet metric | March 31, 2012 | December 31, 2011 |
|---|---|---|
| Cash and cash equivalents | $435,730 | $1,039,190 |
| Total current assets | $656,117 | $1,310,488 |
| Total assets | $716,006 | $1,372,170 |
| Total current liabilities | $485,347 | $541,447 |
| Working capital | Approximately $171,000 | Approximately $769,000 |
| Stockholders’ equity | $230,659 | $830,723 |
The balance sheet lists no outstanding notes payable at March 31, 2012; liabilities consisted primarily of accounts payable, accrued liabilities, and $98,291 due to a related party. No off-balance-sheet arrangements were reported.
Material Changes Versus the Prior Comparable Period
- Total income increased to $195,500 from zero because Nile recognized the final Medtronic collaboration reimbursement. The Medtronic agreement expired in February 2012 after total lifetime reimbursement of $1.55 million.
- R&D expense declined approximately 25% year over year, primarily because of lower stock compensation and reduced outside-consultant use, partly offset by higher cenderitide subcutaneous-study activity.
- G&A expense declined approximately 13%, primarily because of reduced investor-relations services.
- Net loss improved approximately 35% year over year, while operating cash use declined approximately 52%.
- Cash declined approximately 58% from December 31, 2011, and working capital declined approximately 78%.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected substantial and increasing losses and negative operating cash flow as clinical and preclinical development continued.
- Based on March 31 cash and the subsequent financing, management believed funding was sufficient for currently planned operations into the fourth quarter of 2012. Additional financing was required to initiate and complete the planned Phase 2 cenderitide trial.
- The filing stated that these conditions raised substantial doubt about the company’s ability to continue as a going concern. No adjustments for potential inability to continue as a going concern were recorded.
- On April 4, 2012, Nile sold 3.35 million shares at $0.40 per share and issued warrants for 2.5125 million shares at a $0.50 exercise price. Gross proceeds were $1.34 million, with approximately $0.2 million of offering expenses. The warrants’ nonstandard anti-dilution provisions required liability classification.
- Potential contingent milestone payments totaled up to $31.9 million under the cenderitide license and up to $24.3 million under the CU-NP license, subject to clinical and regulatory achievements. No milestone payments were expected in 2012 based on the then-current development stage.
- Cenderitide development remained dependent on financing or a strategic partnership. CU-NP remained preclinical, with minimal external development spending planned until additional capital was obtained.
- Key risks included clinical-trial failure or delay, regulatory nonapproval, inability to obtain financing, dilution, unfavorable licensing or collaboration terms, intellectual-property challenges, dependence on contractors and key personnel, competition, and stock-price volatility.
- On May 14, 2012, Executive Chairman Richard Brewer became a non-employee and his annual compensation was reduced from $240,000 to $100,000.
- Management concluded that disclosure controls and procedures were effective at a reasonable-assurance level, with no material change in internal control over financial reporting during the quarter.
Facts Investors Should Verify
- Verify the issuer: the supplied filing identifies Nile Therapeutics, Inc., while the request identifies Capricor Therapeutics, Inc.
- Verify the April 2012 financing’s net proceeds, warrant liability accounting, anti-dilution terms, and resulting dilution.
- Assess the going-concern disclosure and the company’s ability to secure funding beyond the fourth quarter of 2012.
- Review the financing required for the planned Phase 2 cenderitide trial and the trial’s status, design, and expected cost.
- Review outstanding options and warrants, including approximately 8.66 million warrants outstanding and 7.83 million options outstanding at March 31, 2012.
- Evaluate the contingent Mayo milestone obligations, annual maintenance fees, royalties, and termination provisions.
- Confirm the status and ownership implications of the three patent applications characterized as joint intellectual property with Medtronic.